Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comprehensive tumor-agnostic evaluation of genomic and epigenomic-based approaches for the identification of circulating tumor DNA in early-stage breast cancer

1 Jun 2025

Abstract excerpt

BACKGROUND: The detection of circulating tumor DNA (ctDNA) after curative-intent therapy, referred to as molecular/minimal residual disease (MRD), is prognostic of disease recurrence in early-stage breast cancer (EBC). Tumor-agnostic approaches that rely on mutation-based assessment in fixed panels of common cancer driver genes have shown limited utility for detecting MRD in EBC. Methylation-based MRD (mMRD) may...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Cancer Treatment Studies
Share to Cancer Cells and Metastasis
Share to Cancer Genomics and Diagnostics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40472659
DOI: 10.1016/j.esmoop.2025.105286

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comprehensive tumor-agnostic evaluation of genomic and epigenomic-based approaches for the identification of circulating tumor DNA in early-stage breast cancerPMID 40472659Read ↗

Detection of minimal residual disease and prediction of recurrence in breast cancer using a plasma-only circulating tumor DNA assaySemantic proximity Read ↗

Prognostic value of circulating tumor DNA mutation panels to predict early recurrence and survival outcomes in early-stage breast cancer: a systematic review and meta-analysis.Semantic proximity Read ↗

Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.Semantic proximity Read ↗

Longitudinal evaluation of circulating tumor DNA in patients undergoing neoadjuvant therapy for early breast cancer using a tumor-informed assaySemantic proximity Read ↗

Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast CancerSemantic proximity Read ↗

Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors.Semantic proximity Read ↗

Circulating tumor DNA in neoadjuvant treated breast cancer reflects response and survivalSemantic proximity Read ↗

Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer.Semantic proximity Read ↗

Minimal Residual Disease via circulating tumor DNA Predicts Exceptional Response in HER2-Positive Metastatic Breast CancerSemantic proximity Read ↗

Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival.Semantic proximity Read ↗

Detection of residual disease after neoadjuvant therapy in breast cancer using personalized circulating tumor DNA analysisSemantic proximity Read ↗

Whole genome sequencing-powered ctDNA sequencing for breast cancer detectionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.